January 11, 2022

Now available TEZSPIRE™

TEZSPIRE™ (tezepelumab-ekko), subcutaneous injection,  is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
 
TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.

 

Please see full prescribing information.